What changed
The EMA now requires that protocol submissions for drug utilization studies (DUS) be made within 6 months of CMDh agreement. The first interim report is due 12 months post-protocol approval, followed by subsequent reports every 6 months for two years. The final report should be submitted within 48 months of protocol approval, necessitating compliance with these new timelines and procedures for PSURs.
Why it matters
These changes improve the efficiency and coordination of safety monitoring efforts across EU member states. By standardizing assessment procedures and timelines, MAHs will need to ensure timely reporting and adherence to these guidelines, essential for maintaining patient safety and regulatory compliance.
Action needed
Sign in to unlock the full action card and owner assignment.